APOA1 as a Potential Therapeutic Target and Novel Biomarker in Lung Adenocarcinoma
Cell Biochemistry and Function · 2025
DOI: 10.1002/cbf.70142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Function, 2025. Verfasst von Yuening Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Affiliated Hospital of Nantong University, Pharmacy School of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Apolipoprotein A-I, Adenocarcinoma of Lung, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit nennt 22 Literaturangaben. Gefördert von: This study was supported by Nantong Science and Technology Bureau (No. JC2023036); Nantong Pharmaceutical Society project (No. ntyx2305); National Natural Scie….
Abstract (Originalsprache)
Apolipoprotein A1 (APOA1), the main structural protein of high‐density lipoprotein, has been implicated in cancer, but its role in lung adenocarcinoma (LUAD) remains unclear. Here, we integrate pan‐cancer and LUAD‐focused multi‐omics with patient‐serum validation, in‐vitro and in‐vivo functional assays, and drug‐response/immune‐infiltration analyses to define the role of APOA1. Public datasets (TCGA, HPA, UALCAN, cBioPortal) were used to profile expression, alterations, epigenetics, immune infiltration (CIBERSORT), and pathways (GO/KEGG/GSEA). Serum APOA1 was quantified in 60 LUAD and 30 healthy subjects. APOA1 was overexpressed in A549 and SPCA1 cells to assess proliferation, migration, and invasion; xenografts evaluated in‐vivo growth. Drug‐sensitivity correlations were analyzed. APOA1 is downregulated in LUAD and associates with worse survival; serum levels are reduced. Diagnostic performance was high (AUC = 0.942). APOA1 overexpression suppressed proliferation, migration, and invasion in vitro and reduced tumor volume in vivo. High APOA1 linked to complement/coagulation cascades and distinct immune infiltration. Drug sensitivity analysis revealed enhanced efficacy of agents like selumetinib in high‐APOA1 tumors. This integrated, cross‐layer evidence positions APOA1 as a tumor suppressor and actionable biomarker in LUAD, with implications for early detection, therapeutic stratification, and immunomodulatory strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Affiliated Hospital of Nantong University, Pharmacy School of Nantong University, Nantong, China.
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong, China.
- Department of Clinical Medicine, School of Medicine, Nantong University, Nantong, China.
- Department of Pharmacy, Affiliated Zhongshan Hospital Wusong Branch of Fudan University, Shanghai, China.
- Department of Surgery, Nantong Maternal and Child Health Care Hospital Affiliated to Nantong University, Nantong, China.
- The Affiliated Yancheng First Hospital of Nanjing University Medical School, The First People's Hospital of Yancheng.
ORCID-Profile: Zheng Yang
Förderung
- This study was supported by Nantong Science and Technology Bureau (No. JC2023036); Nantong Pharmaceutical Society project (No. ntyx2305); National Natural Scie…
Zitieren
APA
Sun, Y., Shen, J., Lin, Y., Yang, Z., Sang, H., Lu, L., Zhou, H., Xu, X., Huang, J., & Zhou, X. (2025). APOA1 as a Potential Therapeutic Target and Novel Biomarker in Lung Adenocarcinoma. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70142
Vancouver
Sun Y, Shen J, Lin Y, Yang Z, Sang H, Lu L, et al. APOA1 as a Potential Therapeutic Target and Novel Biomarker in Lung Adenocarcinoma. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70142
BibTeX
@article{Sun2025,
author = {Sun, Yuening and Shen, Jie and Lin, Yizhou and Yang, Zheng and Sang, Hua and Lu, Liu and Zhou, Huijun and Xu, Xin and Huang, Jinshi and Zhou, Xiaoyu},
title = {APOA1 as a Potential Therapeutic Target and Novel Biomarker in Lung Adenocarcinoma},
journal = {Cell Biochemistry and Function},
year = {2025},
doi = {10.1002/cbf.70142}
}
EUVIMED